Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells

Nathan Simon, …, Christine Alewine, David FitzGerald

*JCI Insight*. 2019;4(5):e123281. [https://doi.org/10.1172/jci.insight.123281](https://doi.org/10.1172/jci.insight.123281).

The routes by which antibody-based therapeutics reach malignant cells are poorly defined. Tofacitinib, an FDA-approved JAK inhibitor, reduced tumor-associated inflammatory cells and allowed increased delivery of antibody-based agents to malignant cells. Alone, tofacitinib exhibited no antitumor activity, but combinations with immunotoxins or an antibody-drug conjugate resulted in increased antitumor responses. Quantification using flow cytometry revealed that antibody-based agents accumulated in malignant cells at higher percentages following tofacitinib treatment. Profiling of tofacitinib-treated tumor-bearing mice indicated that cytokine transcripts and various proteins involved in chemotaxis were reduced compared with vehicle-treated mice. Histological analysis revealed significant changes to the composition of the tumor microenvironment, with reductions in monocytes, macrophages, and neutrophils. Tumor-associated inflammatory cells contributed to non-target uptake of antibody-based therapeutics, with mice treated with tofacitinib showing decreased accumulation of therapeutics in intratumoral inflammatory cells and increased delivery to malignant cells. The present findings serve as a rationale for conducting trials where short-term treatments with tofacitinib could be administered in combination with antibody-based therapies.

Find the latest version:

[http://jci.me/123281/pdf](http://jci.me/123281/pdf)
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells

Nathan Simon,1 Antonella Antignani,1 Stephen M. Hewitt,1 Massimo Gadina,2 Christine Alewine,1 and David FitzGerald1

1Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA.

Introduction

Overcoming treatment resistance is a major goal of cancer research. Various cell types within the tumor microenvironment (TME) have been posited as barriers to effective treatment including macrophages (1, 2), monocytes (3), fibroblasts (4), neutrophils (5), regulatory T cells (6), and endothelial cells (7). These stromal cells, together with secreted factors, can protect malignant cells from a variety of therapies including cytotoxic drugs (7, 8). Likewise, the adaptive immune system works poorly in an immunosuppressive tumor environment where alternatively polarized macrophages, myeloid-derived suppressor cells (MDSCs), or regulatory T cells are present (9–11). Aberrant vascular architecture leading to hypoxia and irregular vessel formation, resulting in poor drug delivery, has prompted the development of vasculature-normalizing agents with the goal of improving access to malignant cells (7, 12). When antibody-based agents are employed, high levels of shed antigen or antigen-negative variants can result in poor treatment outcomes (13, 14). In addition, there is speculation that high numbers of inflammatory cells can interfere with delivery to malignant cells (15). To address this, here we investigate antibody delivery to malignant cells following treatment of tumor-bearing mice with the JAK/STAT inhibitor, tofacitinib.

So-called naked antibodies, including rituximab, cetuximab, and trastuzumab, were some of the first antibody-based therapeutics to be developed and have been approved for many years. More recently, antibody-drug conjugates (ADCs), immunotoxins, chimeric antigen receptor (CAR) T cells, bispecific T cell engagers (BiTEs), and checkpoint inhibitor antibodies have been approved. With the exception of checkpoint inhibitors, antibody therapeutics must be delivered directly to malignant cells where they bind surface antigens or receptors. Antibodies are effective either because they nullify essential growth signals, recruit effector cells, or deliver cytotoxic payloads. However, failure to contact malignant cells is likely to lead to a poor response. The routes by which antibodies reach malignant cells within the larger TME have not been extensively documented.

The routes by which antibody-based therapeutics reach malignant cells are poorly defined. Tofacitinib, an FDA-approved JAK inhibitor, reduced tumor-associated inflammatory cells and allowed increased delivery of antibody-based agents to malignant cells. Alone, tofacitinib exhibited no antitumor activity, but combinations with immunotoxins or an antibody-drug conjugate resulted in increased antitumor responses. Quantification using flow cytometry revealed that antibody-based agents accumulated in malignant cells at higher percentages following tofacitinib treatment. Profiling of tofacitinib-treated tumor-bearing mice indicated that cytokine transcripts and various proteins involved in chemotaxis were reduced compared with vehicle-treated mice. Histological analysis revealed significant changes to the composition of the tumor microenvironment, with reductions in monocytes, macrophages, and neutrophils. Tumor-associated inflammatory cells contributed to non-target uptake of antibody-based therapeutics, with mice treated with tofacitinib showing decreased accumulation of therapeutics in intratumoral inflammatory cells and increased delivery to malignant cells. The present findings serve as a rationale for conducting trials where short-term treatments with tofacitinib could be administered in combination with antibody-based therapies.
Desmoplastic tumors like pancreatic or triple-negative breast cancers (TNBCs) are characterized by abundant extracellular matrix (ECM) and tumor infiltration of inflammatory immune cell populations like MDSCs and tumor-associated macrophages or neutrophils (TAMs or TANs), which can hinder therapeutic efficacy (16, 17). In addition to aggressive growth and metastatic potential, pancreatic ductal adenocarcinomas (PDACs) and TNBCs lack effective targeted therapies, instead relying on conventional chemotherapies that often result in drug-resistant relapse and progression (18, 19). PDACs have a 5-year survival rate of 5%–10% (20) and disease severity correlates with increased inflammation and stromal contributions to tumor growth (21, 22). In particular, the presence of TANs is correlated with poorer outcomes and resistance to chemotherapies and checkpoint inhibitors (23). Like pancreatic cancers, TNBC progression relies on significant contribution from the tumor stroma and inflammatory cell populations, with accumulation of collagen-rich fibrotic lesions and the subsequent release of neutrophil chemoattractants from fibroblasts responsible for recruiting inflammatory cells (24, 25). However, monocytes and neutrophils are relatively short-lived, requiring continuous release of cytokines from the growing tumor to recruit and replenish these cells. If cytokines could be downregulated, the TME would undoubtedly be altered, possibly allowing a more favorable situation for therapeutic intervention, including improved delivery of antibody-based agents.

Integral to the development of antibody-based agents is the necessity to identify surface antigens expressed prominently or exclusively on tumorigenic cells, but not on vital normal tissues (26–28). These antigens have become targets for such antibody-directed therapeutics as immunotoxins and ADCs (29). Immunotoxins consist of an antibody fragment or receptor ligand targeting a surface antigen/receptor joined to a plant or bacterial toxin component, typically ricin or saporin, diphtheria toxin, or Pseudomonas aeruginosa exotoxin A (PE) (30). The catalytic inhibition of protein synthesis makes immunotoxins highly potent, with estimates suggesting that a small number of toxin molecules delivered to the cytosol is sufficient to kill a susceptible cell (31). This potency has led to the testing of immunotoxins in clinical trials for treatment of aggressive tumors, including brain (32), mesothelioma (33), and pancreatic (34) cancers, as well as hematologic cancers (35–37). Specifically, the immunotoxin LMB-100, which targets surface mesothelin, is being evaluated in clinical trials for malignant mesothelioma and pancreatic cancer (NCT02810418 and NCT02798536). In contrast, ADCs are typically full-length antibodies conjugated to potent cytotoxic drugs that must be delivered in sufficient quantities to inhibit DNA replication or cell division (38). ADCs have also been tested in a variety of clinical settings, exhibiting several notable successes (39, 40). However, all antibody-based therapeutics rely on efficient delivery to the malignant cell population, as inefficient delivery often necessitates increased dosing, risking significant off-target toxicities.

With this as background, we set out to evaluate the in vivo activity of the pan-JAK inhibitor tofacitinib, in combination with antibody-based therapeutics targeting pancreatic cancer and TNBC models. The initial rationale for this evaluation came from earlier studies showing that tofacitinib could reduce antidrug immune responses that often accompany the administration of immunotoxins to individuals or test animals that have an intact immune system (41). In addition, rheumatoid arthritis (RA) patients treated with tofacitinib show potent inhibition of JAK/STAT signaling and a subsequent decrease in circulating proinflammatory cytokines resulting in fewer inflammatory cells within arthritic lesions (42, 43). As tofacitinib inhibits both proinflammatory signaling and the antidrug immune response, it was evaluated in combination with immunotoxin therapy. These experiments were then extended to include a mesothelin-targeted ADC currently under clinical development (44). We report that tofacitinib enhanced the antitumor activity of both immunotoxins and the ADC. Mechanistic insights suggested that enhancement was associated with decreased cytokine production and decreased recruitment of TAMs and TANs to the tumor. In turn, this resulted in a decrease in off-target uptake of therapeutic molecules by these inflammatory cell populations, leading to enhanced delivery of antibody-based agents to the malignant cells. These preclinical results provide a rationale for human trials combining tofacitinib with a variety of antibody-based therapeutics.

Results

Tofacitinib enhances immunotoxin activity in vivo. In humans, the pan-JAK inhibitor tofacitinib reduces joint inflammation and immune cell infiltrates associated with RA (42, 43, 45). In mice, tofacitinib reduces antibody responses to foreign proteins including immunotoxins (41); therefore, it was of interest to test tofacitinib in combination with the antitumor activity of immunotoxins, first in a xenograft model of TNBC. MDA-MB-468 tumors were treated with vehicle, tofacitinib alone, immunotoxin alone, or a combination of both. Tumors in vehicle- or tofacitinib-treated groups (n = 6 per group) quickly reached the experimental
The endpoint of 1,200 mm$^3$ (Figure 1A), with median survival of 33.5 and 36.5 days, respectively ($P = 0.478$) (Figure 1B). Tumors in mice treated with the immunotoxin (HB21-PE40, targeting the human transferrin receptor) displayed a brief but significant delay in tumor growth (Figure 1A). Median survival for immunotoxin-treated mice was 47 days, significantly improved over vehicle-treated mice ($P < 0.001$) (Figure 1B).

Treatment of tumors with the combination therapy resulted in enhanced antitumor activity, with an initial decrease in tumor volume during treatment followed by a sustained delay of tumor growth for several weeks ($P < 0.001$) (Figure 1A). Median survival of combination-treated mice was significantly longer than mice treated with immunotoxin alone, with a median time to death of 64 days ($P < 0.001$) (Figure 1B). A second experimental replicate showed similar results (Supplemental Figure 1, A and C; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.123281DS1).

Using the same treatment strategy, we next challenged the KLM-1 PDAC tumor model with the investigational immunotoxin LMB-100, which targets surface mesothelin (46). A preliminary experiment using only 1 treatment cycle proved less effective than in the TNBC model (Supplemental Figure 1, B and D). Therefore, we designed a second experiment whereby mice ($n = 7$ or $8$ per group) received 2 cycles of treatment spaced 1 week apart (Figure 1C). As before, tumors in mice treated with vehicle or tofacitinib grew rapidly, with median time to endpoint of 28 days for each group (Figure 1D). Tumors treated with the LMB-100 immunotoxin showed reduced tumor growth compared with vehicle-treated tumors ($P < 0.001$), but no decrease in tumor volume and rapid regrowth after treatment. In contrast, tumors treated with LMB-100 plus tofacitinib showed a decrease in tumor volume during each treatment cycle, and delayed tumor regrowth after treatment. Median endpoint was not reached until 48 days, significantly extended from both vehicle- and tofacitinib-treated mice ($P < 0.001$) and from LMB-100–treated mice ($P = 0.0013$). Two combination-treated mice showed minimal tumor growth, but no complete regression and were sacrificed at 60 days. In both xenograft models, combination treatments were clearly more effective at inhibiting tumor growth than single agents.
Tofacitinib does not enhance immunotoxin activity in vitro. To gain insight into the mechanism of increased immunotoxin activity, we investigated whether tofacitinib caused similar enhancements in tissue culture. Tofacitinib at concentrations of 1, 2, and 4 μM did not increase the cytotoxic activity of either immunotoxin targeting MDA-MB-468 or KLM-1 cells (Supplemental Figure 2, A and B). Tofacitinib alone, at concentrations up to 16 μM, had no appreciable effect on the viability of either cell line (Supplemental Figure 2, C and D) and also failed to enhance immunotoxin action (Supplemental Figure 2, E and F).

Tofacitinib targets both JAK3 and JAK1 signaling and, to a lesser extent, JAK2 (47). However, cells of epithelial origin typically do not express JAK3 but can express either JAK1 or JAK2, which in turn can activate downstream STAT proteins. To determine if the lack of immunotoxin enhancement in tissue culture was due to poor JAK inhibition, we examined the status of downstream STAT proteins. Untreated, KLM-1 cells showed activation of both STAT1 and STAT3, whereas tofacitinib treatment eliminated detectable p-STAT3 (Supplemental Figure 2G). STAT1 activation was impacted only moderately. Similar results were obtained for MDA-MB-468 cells, which showed a robust p-STAT3 signal, consistent with the constitutive activation of STAT3 in many breast cancers (48) (Supplemental Figure 2H). Tofacitinib treatment completely abrogated p-STAT3, but did not alter STAT1 phosphorylation. Our results confirmed that tofacitinib inhibited the phosphorylation of relevant downstream JAK effectors in both cell lines and that failure to enhance immunotoxin action in tissue culture was unrelated to drug resistance or aberrant signaling pathways.

Tofacitinib treatment enhances tumor uptake of antibody-based therapeutics. As tofacitinib enhanced the antitumor activity of immunotoxins in vivo, but displayed no single-agent activity and no enhancement in vitro, we considered that tofacitinib was altering the TME, either permitting increased immunotoxin access to tumor cells.
cells or altering survival or proliferation signals. To examine the first possibility, we quantified the delivery of fluorescently labeled immunotoxin to tumor cells in xenograft models. Tumor-bearing mice were pretreated for approximately 70 hours with either vehicle or tofacitinib and then administered fluorescently labeled immunotoxin. Based on immunotoxin half-life and prior studies examining tumor uptake (49), tumors were excised 3 hours after injection, enzymatically dissociated into single-cell suspensions, and analyzed for immunotoxin uptake by flow cytometry (Supplemental Figure 3, A and B). Tumor cells were identified via gating with a human-specific antibody against the epidermal growth factor receptor (EGFR) to ensure that only uptake into malignant cells was analyzed.

When KLM-1 tumors were retrieved from mice injected with fluorescently labeled LMB-100 (LMB-100–Alexa647), the average \( n = 4 \) independent experiments) labeling of recovered malignant cells approached a median of 29% at 3 hours after injection. However, when mice were pretreated with tofacitinib, 43% of malignant cells exhibited an immunotoxin signal (Figure 2A) \( P = 0.04 \). Similarly, mice bearing MDA-MB-468 tumors and treated with Alexa647-labeled HB21-PE40 for 3 hours showed increased tumor cell uptake of labeled immunotoxin in mice pretreated with tofacitinib compared with mice treated with vehicle (Figure 2B) \( P = 0.05 \). These results confirmed a tofacitinib-mediated increase in the delivery of immunotoxin to tumor cells and suggested a potential explanation for the enhancement of immunotoxin activity.

To determine if tofacitinib-mediated enhancement of delivery was applicable to other antibody-based therapeutics, tumor uptake of a fluorescently labeled full-length antibody was investigated. TNBCs often overexpress the EGFR and up to 90% of PDACs show EGFR overexpression. Therefore, mice with KLM-1 (Figure 2C) or MDA-MB-468 (Figure 2D) xenografts were injected with a fluorescently labeled anti-EGFR monoclonal antibody following tofacitinib or vehicle pretreatment. With vehicle-treated mice, a median of 13% of KLM-1 tumor cells, identified with an antibody against the human transferrin receptor (TfnR), were...
associated with a positive anti-EGFR–BV421 signal. However, with tofacitinib pretreatment, 20% of tumor cells showed positive signal ($P = 0.004$) (Supplemental Figure 3B). Similarly, MDA-MB-468 tumors showed an increase in antibody uptake when treated with both anti-EGFR and tofacitinib compared with tumors treated with anti-EGFR plus vehicle (9.3% to 4.0%; $P = 0.04$). Like the uptake of immunotoxins, tumors from mice receiving tofacitinib treatment showed a 1.5- to 2-fold increase in the number of cells exhibiting EGFR antibody binding over tumors treated with vehicle, supporting the hypothesis that improved tumor access for antibody-based therapeutics may be a broadly applicable property of tofacitinib treatment.

Additionally, we chose to investigate whether tofacitinib could similarly enhance ADC delivery through evaluation of tofacitinib's effects on the antitumor activity of anetumab ravtansine, a mesothelin-targeted ADC with reported antitumor activity in both preclinical and clinical studies against mesothelin-positive malignancies (44). The combination of tofacitinib and anetumab ravtansine in tissue culture showed no enhancement of KLM-1 killing (Figure 3A). However, in vivo, combinations with tofacitinib enhanced the antitumor effects of anetumab ravtansine, with tumor growth significantly delayed compared with anetumab ravtansine alone ($P = 0.002$) (Figure 3B). Treatment with anetumab ravtansine alone resulted in modest inhibition of tumor growth and a 35% increase in survival over untreated tumors ($P = 0.04$). As before, tofacitinib exhibited no significant antitumor activity alone. While the amount of antibody required for an observable effect was high (10 mg/kg), this dosage is comparable to published reports. Additionally, independent experiments with lower anetumab ravtansine dosing showed similar trends of enhancement, albeit with lower-magnitude effects (Supplemental Figure 4, A–D), confirming a tofacitinib-mediated enhanced delivery of this therapeutic. Thus, pretreatments of tumor-bearing mice with tofacitinib had the general effect of enhancing antibody-mediated antitumor efficacy, suggesting the existence of treatment barriers that limit the effectiveness of antibody-based therapeutics.

Tofacitinib-mediated downregulation of inflammatory cytokine and arginase expression. Tofacitinib did not enhance immunotoxin activity in tissue culture, but enhanced therapeutic uptake in vivo, suggesting action at the level of the tumor itself. To determine if tofacitinib inhibition of JAK/STAT signaling could alter the TME transcriptome, RNA was isolated from KLM-1 tumors that had received no treatment, vehicle alone, or tofacitinib. Transcript profiles for murine immune-related genes were then evaluated by Nanostring technology. Transcript counts similar between vehicle and untreated tumors but altered in tofacitinib-treated tumors were identified by agglomerative clustering analysis (Supplemental Figure 5). Differential expression of this subset of genes was then determined for vehicle- and tofacitinib-treated tumors, and genes with at least 2-fold downregulation identified (Table 1). Tofacitinib-downregulated transcripts could be broadly grouped into 3 functional categories: neutrophil/granulocyte chemokines, monocyte chemokines, and B cell activation proteins. The transcripts showing the greatest reductions in tofacitinib-treated tumors were neutrophil chemokines (Ccl3 (–7.46-fold) and Cxcl3 (–6.29-fold), with monocyte chemokines (Ccl4, –3.62-fold; Ccl2, –3.35-fold, Cxcl1, –2.86-fold) and B cell activation pathway components (Pax5, –3.78-fold; Il13, –2.48-fold) also reduced (Table 1). Transcripts for arginase-1 (–2.37-fold) and cyclooxygenase 2 (COX-2) (–1.58-fold), which are often highly expressed in MDSCs and suppress antitumor immune activity, were also downregulated. Fewer genes were upregulated in tofacitinib-treated KLM-1 tumors compared with vehicle/untreated tumors (Table 2). The most differentially expressed gene was that encoding interferon-α (+3.85-fold), an antiviral cytokine that stimulates natural killer (NK) cell cytotoxic activity upon STAT1 inhibition (50). However, genes upregulated by tofacitinib treatment did not obviously cluster into functional groupings and were not studied further.

Nanostring analysis revealed that tofacitinib treatment showed the largest effect on transcription of neutrophil and monocyte chemoattractants. To determine if transcript changes correlated with protein levels, CXCL2 and CCL4 serum levels were analyzed by ELISA. Furthermore, circulating IL-6 and CCL2 levels were analyzed because these cytokines are routinely lowered in RA patients treated with tofacitinib (42, 51). Non–tumor-bearing mice displayed low levels of circulating CXCL2 (15.4 pg/ml) and essentially undetectable levels of circulating CCL4 (2.3 pg/ml). Tumor-bearing mice showed upregulation of both chemokines (CXCL2, 61.8 pg/ml; CCL4, 38.4 pg/ml), indicating that the tumor had stimulated production (Figure 4A). Treatment with tofacitinib significantly reduced serum levels of both chemokines, decreasing CXCL2 to 25.1 pg/ml, only a 1.6-fold increase over naive mice ($P < 0.001$). Circulating CCL4 was similarly reduced, from 38.4 pg/ml in vehicle-treated tumors to 8.4 pg/ml in tofacitinib-treated mice ($P = 0.02$). Naive mice showed slightly higher levels of CCL2 compared with the other chemokines (30.6 pg/ml); however, in mice bearing KLM-1 tumors, circulating CCL2 doubled to 61 pg/ml. Treatment with tofacitinib reduced this expression to 38.9 pg/ml ($P = 0.004$). Mice bearing KLM-1 tumors showed a mini-
mal increase in IL-6 over naive mice (33.6 to 38.1 pg/ml), which was abrogated in tofacitinib-treated mice (32.7 pg/ml) (Figure 4B). However, mice with MDA-MB-468 tumors showed a tripling of circulating IL-6 compared with naive mice (33.6 to 87.1 pg/ml), consistent with the role that IL-6 plays in TNBC growth and metastasis. Treatment with tofacitinib resulted in a significant decrease in IL-6, to levels comparable to naive mice (32.8 pg/ml) ($P = 0.01$). These data confirmed that tofacitinib reduced key cytokines associated with inflammatory cell recruitment and tumorigenesis.

The presence of TANs, MDSCs, and TAMs is linked frequently to a tumor-permissive environment through release of proinflammatory cytokines and production of immune-suppressing molecules like arginase-1 or COX-2 (52–54). As arginase expression is regulated by STAT signaling (55) and showed more than 2-fold downregulation of the transcript level upon tofacitinib treatment (Table 1), changes in arginase activity levels within tumors were also examined. The enzymatic activity of arginase-1 in tumor supernatants was measured through the conversion of L-arginine to urea (56). Tofacitinib treatment of KLM-1 xenografts showed an approximately 20% reduction in tumor-associated arginase activity compared with vehicle-treated tumors ($P = 0.02$) (Figure 4C). Treatment of MDA-MB-468 xenografts with tofacitinib showed a similar trend, significantly reducing tumor-associated arginase enzymatic activity to 43% of that of vehicle-treated tumors ($P = 0.03$) (Figure 4C). Taken together, these data suggested that tofacitinib alters the TME by reducing the recruitment and/or activity of certain immune populations.

**Tofacitinib reduces recruitment of TANs, TAMs, and myeloid cells.** To determine whether tofacitinib treatment altered the composition of the tumor, mice were treated with vehicle or tofacitinib (Figure 5A). Given the depletion of myeloid cell and neutrophil chemotactic proteins, antibodies reactive for markers of myeloid cells (α-CD11b or α-LY6G), neutrophils (α-myeloperoxidase [α-MPO]) or α-LY6G), or murine macrophages (α-F4/80) were utilized to determine if these inflammatory cell populations within the tumor were altered by tofacitinib treatment. Images were captured for each treatment group and scored for the presence and quantity of each cell marker from at least 20 random fields for each treatment. In KLM-1 tumors, TAMs were obviously depleted in tofacitinib-treated animals compared with vehicle-treated tumors (Figure 5A). Vehicle-treated tumors showed a median of 42 F4/80+ cells

<table>
<thead>
<tr>
<th>mRNA symbol</th>
<th>Fold-change (T/V)</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cxcl2</td>
<td>−7.46</td>
<td>Neutrophil chemoattractant</td>
</tr>
<tr>
<td>Cxcl3</td>
<td>−6.29</td>
<td>Neutrophil chemoattractant</td>
</tr>
<tr>
<td>Pax5</td>
<td>−3.78</td>
<td>B cell activation</td>
</tr>
<tr>
<td>Ccl4</td>
<td>−3.62</td>
<td>Monocyte chemoattractant</td>
</tr>
<tr>
<td>Psmb10</td>
<td>−3.47</td>
<td>Proteasome component</td>
</tr>
<tr>
<td>Ccl1</td>
<td>−3.35</td>
<td>Monocyte chemoattractant</td>
</tr>
<tr>
<td>Lck</td>
<td>−3.35</td>
<td>Proto-oncogene tyrosine kinase</td>
</tr>
<tr>
<td>Cd274</td>
<td>−3.22</td>
<td>PD-L1</td>
</tr>
<tr>
<td>Cd209</td>
<td>−3.19</td>
<td>Macrophage and DC lectin</td>
</tr>
<tr>
<td>Tnfsf13b</td>
<td>−3.12</td>
<td>Stimulates B cell activation</td>
</tr>
<tr>
<td>Ccl3</td>
<td>−2.86</td>
<td>Monocyte chemoattractant</td>
</tr>
<tr>
<td>Sele</td>
<td>−2.64</td>
<td>Endothelial cell lectin</td>
</tr>
<tr>
<td>Il2rb</td>
<td>−2.62</td>
<td>Treg differentiation</td>
</tr>
<tr>
<td>Klrk1</td>
<td>−2.57</td>
<td>NK cell lectin</td>
</tr>
<tr>
<td>C6</td>
<td>−2.52</td>
<td>Complement factor</td>
</tr>
<tr>
<td>Il13</td>
<td>−2.48</td>
<td>Promotes B cell differentiation</td>
</tr>
<tr>
<td>Arg1</td>
<td>−2.37</td>
<td>Inhibits NK cells and CD8+ T cells</td>
</tr>
<tr>
<td>Il15ra</td>
<td>−2.28</td>
<td>Proliferation and antiapoptosis</td>
</tr>
<tr>
<td>Dpp4</td>
<td>−2.25</td>
<td>T cell receptor</td>
</tr>
<tr>
<td>Siglec1</td>
<td>−2.15</td>
<td>Macrophage lectin</td>
</tr>
<tr>
<td>Cd22</td>
<td>−2.08</td>
<td>B cell lectin</td>
</tr>
<tr>
<td>Ifna2</td>
<td>−2.06</td>
<td>Stimulates JAK/STAT1 signaling</td>
</tr>
<tr>
<td>Ccr6</td>
<td>−2.01</td>
<td>B cell activation</td>
</tr>
</tbody>
</table>
per field (range, 7–140), which was significantly reduced in tofacitinib-treated animals to 18 cells/field (range, 6–88) ($P < 0.01$). Tumor-associated CD11b$^+$ myeloid cells also decreased in response to tofacitinib treatment (Figure 5B). Vehicle-treated tumors showed CD11b$^+$ cells scattered throughout the tumor stroma, while these cells were barely detectable in tofacitinib-treated tumors. Vehicle-treated tumors scored a median of 20 CD11b$^+$ cells per field (range, 3–45), while treatment with tofacitinib significantly reduced this number to 1 cell/field (range, 0–8) ($P < 0.001$). Similarly, vehicle-treated tumors showed MPO$^+$ cells (arrowheads) within the stroma, but also among the tumor cells (Figure 5C). The population of MPO$^+$ cells was also altered significantly in tofacitinib-treated tumors, as MPO$^+$ cells decreased by approximately 80% compared with vehicle, from a median of 20 MPO$^+$ cells/field of view (range, 2–88) to 3 MPO$^+$ cells per field (range, 0–47) ($P < 0.001$) (Figure 5C). Finally, to confirm that TANs were depleted by tofacitinib, a second granulocyte marker, LY6G, was examined (Figure 5D). Vehicle-treated tumors showed a median of 17 LY6G$^+$ cells/field of view (range, 0–104), again in both the tumor stroma and among the malignant cells. Tofacitinib significantly reduced LY6G$^+$ cells to a median of merely 1 cell/field (range, 0–41).

Similar trends were noted for IHC staining of inflammatory cell populations in MDA-MB-468 tumors (Supplemental Figure 6A), although there were fewer inflammatory cells overall. Tofacitinib treatment modestly, but significantly, reduced median CD11b$^+$ cells compared with vehicle from 9 (range, 0–60) to 4 (range, 0–28) (Supplemental Figure 6B, $P = 0.009$). As the CD11b$^+$ staining in MDA-MB-468 tumors was less well defined than in KLM-1 tumors, we also identified myeloid cells using the GR1-LY6G marker. Tofacitinib similarly resulted in a moderate reduction in tumor-associated GR1-LY6G$^+$ cells from a median of 16 cells/field (range, 5–46) to 12 (range, 0–32) ($P = 0.04$) (Supplemental Figure 6D). Vehicle-treated tumors showed a median of 18 MPO$^+$ cells/field (range, 0–41), while tofacitinib-treated tumors only had 8 MPO$^+$ cells/field (range, 0–46) ($P = 0.04$). In the above experiments, tumors were harvested 3 days after receiving the first injection of tofacitinib and then scored for the presence of short-lived inflammatory cells: neutrophils (typical $t_{1/2}$ of less than a day), monocytes ($t_{1/2}$ of 1–2 days), and TAMs, which were substantially lowered after 3 days treatment with other macrophage-depleting agents. Our data confirm that short-duration treatments can result in tofacitinib-mediated depletion of chemokine levels and reduced recruitment of inflammatory cells into the TME.

### Tofacitinib treatment reduces tumor-associated inflammatory cells in a syngeneic breast cancer model

Xenograft tumor models allow therapeutic compounds to be evaluated against human cancers in a living animal. However, the absence of effector T cells does not permit an adaptive immune response. To investigate tofacitinib activity in an animal with an intact immune system, a syngeneic tumor model of breast cancer was evaluated. 4T-1 mammary carcinoma cells were implanted in the mammary pad of female BALB/c mice and treated with tofacitinib or vehicle, and IHC was performed to assess the effect of tofacitinib on cell recruitment into the TME (Supplemental Figure 7, A–D). Similar to results in the xenograft models, tumor-associated inflammatory cells were reduced following tofacitinib treatment, with significant decreases noted in the number of CD11b$^+$ cells ($P = 0.04$), MPO$^+$ cells ($P < 0.001$), LY6G$^+$ granulocytes ($P < 0.001$), and F4/80$^+$ macrophages ($P = 0.002$). However, as seen in both xenograft tumor models, no significant differences in tumor growth rate were recorded with tofacitinib treatments, suggesting that antitumor cell functions that otherwise might

### Table 2. Mouse genes showing greater than 2-fold upregulation in mRNA transcript levels after tofacitinib treatment (T) compared with vehicle-treated (V) mice

<table>
<thead>
<tr>
<th>mRNA Symbol</th>
<th>Fold-change (T/V)</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ifna1</td>
<td>3.85</td>
<td>Stimulates NK cell activity</td>
</tr>
<tr>
<td>Aicda</td>
<td>3.26</td>
<td>Cytidine deaminase</td>
</tr>
<tr>
<td>H2-Eb1</td>
<td>2.75</td>
<td>Histocompatibility II antigen</td>
</tr>
<tr>
<td>Tpsab1</td>
<td>2.37</td>
<td>Mast cell tryptase</td>
</tr>
<tr>
<td>Timd4</td>
<td>2.36</td>
<td>Stimulates T cell proliferation</td>
</tr>
<tr>
<td>Il13ra2</td>
<td>2.27</td>
<td>Promotes B cell maturation</td>
</tr>
<tr>
<td>Ca59b</td>
<td>2.19</td>
<td>Complement pathway</td>
</tr>
<tr>
<td>Il17b</td>
<td>2.03</td>
<td>Regulation of NF-$\kappa$B</td>
</tr>
</tbody>
</table>
be keeping the tumor in check were not significantly compromised under these short-duration treatment regimens. (Supplemental Figure 7E). Arginase enzymatic activity within the syngeneic 4T-1 breast cancer tumors was also measured as before, with tofacitinib treatment reducing tumor-associated arginase activity to 68% of that of vehicle-treated tumors (Supplemental Figure 7F, *P* < 0.001).

**Non-target uptake of immunotoxins by tumor-associated inflammatory cells.** The reduction in tumor-associated inflammatory cells following tofacitinib treatments coupled with enhanced uptake of antibodies into malignant cells suggested that inflammatory cells could be altering therapeutic protein availability. To address this, we first investigated whether tofacitinib altered the pharmacokinetics of immunotoxin metabolism. Sera from mice bearing KLM-1 tumors pretreated with tofacitinib or vehicle were harvested at 0, 15, 30, 45, and 60 minutes after injection and assayed for LMB-100 immunotoxin levels by ELISA (Figure 6A). Mice treated with vehicle had an immunotoxin half-life of 25 minutes, similar to previous reports (57), while mice treated with tofacitinib had a half-life of 46 minutes (*P* = 0.02). Tofacitinib additionally

![Figure 4. Tofacitinib treatment reduces the levels of circulating proinflammatory chemokines and tumor-associated arginase.](image-url)
increased the immunotoxin exposure (area under the curve from \( t = 0 \) to \( t = 60 \)) by 35%, suggesting that malignant cells had a greater exposure to immunotoxin molecules. Likewise, drug levels for the immunotoxin HB21-PE40 were analyzed kinetically in mice bearing MDA-MB-468 tumors, with vehicle-treated tumors showing an immunotoxin half-life of 15 minutes, while mice treated with tofacitinib had a half-life of 30 minutes (Supplemental Figure 8A, \( P = 0.04 \)). These data confirmed that tofacitinib increased the amount of immunotoxin available to interact with malignant cells, potentially by reducing inflammatory cell clearance of immunotoxin, minimally at the tumor itself, but possibly at other locations. To determine if tofacitinib acted mainly on inflammatory cell populations stimulated by the presence of a malignancy, or on inflammatory cells in general, a similar experiment was performed in naive mice. As before, sera from mice pretreated with tofacitinib or vehicle and injected with LMB-100 were harvested at 0, 15, 30, 45, and 60 minutes after injection and assayed for LMB-100 immunotoxin levels by ELISA (Figure 6B). Naive mice showed an LMB-100 half-life of 23 minutes, while tofacitinib-treated mice had an increased half-life...
of 32 minutes ($P = 0.66$). Treatment with tofacitinib increased immunotoxin exposure by almost one-third compared with vehicle-treated mice, suggesting that tofacitinib may be acting more generally and not just on tumor-associated inflammatory cells. If antibodies targeted to malignant cells are ingested or otherwise depleted by inflammatory cells, then peritumoral scavenging may result in less effective therapies. To address this specifically, the cellular fate of fluorescently labeled immunotoxin in tumor-bearing mice was further investigated; immunotoxins rather than full-length antibodies were chosen to both avoid potentially confounding results with Fc receptor–mediated uptake, as well as to stay consistent with our previous antitumor studies. KLM-1 tumors from mice pretreated with tofacitinib or vehicle and injected with LMB-100 and blood was harvested at $t = 0$, 15, 30, 45, and 60 minutes. Circulating LMB-100 was detected by ELISA and normalized to a standard curve for purified LMB-100. The half-life and area under the curve were calculated from best-fit regression analysis. Results are averaged from 2 biological replicates. (B) Naive mice were treated with vehicle or tofacitinib at $t = -48$ and -24 hours. At $t = 0$, mice were injected with LMB-100 and blood was harvested at $t = 0$, 15, 30, 45, and 60 minutes. Circulating LMB-100 was detected by ELISA and normalized to a standard curve for purified LMB-100. The half-life and area under the curve were calculated from best-fit regression analysis. Results are averaged from 4 biological replicates. (C) Mice bearing KLM-1 xenografts were pretreated with either vehicle or tofacitinib, then administered 50 μg LMB-100–A647 for 3 hours. Dissociated tumors were scored for the presence of LMB-100–A647 in malignant cells and inflammatory populations. Tumor cells were identified by staining with anti–huEGFR, and tumor-associated inflammatory cell populations were identified by staining with anti–mCD11b. The percentage of huEGFR or mCD11b cells containing immunotoxin in vehicle or tofacitinib-treated mice is shown. $n = 4$ biological replicates. (D) CD11b+ cells containing LMB-100–A647 were further discriminated into CD68+ (macrophage) or LY6G+ (neutrophil) populations. The percentage of tumor-associated LMB-100–A647+ cells displaying each cell marker is shown. $n = 4$ biological replicates. *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$ by unpaired 2-tailed t test (A–D), ns, not significant.
ed LMB-100–A647 (P = 0.05), but only a minimal reduction in granulocyte-associated immunotoxin (Figure 6D). Concurrent with the reduction in mCD11b–LMB100–A647+ cells in tofacitinib-treated tumors was an increase in huEGFR+LMB100–A647+ cells compared with vehicle-treated tumors (tofacitinib, 34% vs. 22% vehicle; P < 0.001).

In tumor-bearing animals, inflammation is not confined to the TME but also noted in the spleen, a significant source of precursor inflammatory cells which transit to the tumor, differentiate into TAMs/TANs, and accumulate within the tumor (58, 59). Therefore, we examined spleens from tumor-bearing mice with and without tofacitinib treatment. In mice bearing KLM-1 tumors, we noted a 25% increase in spleen weight (0.22 ± 0.02 g, n = 4) compared with naive mice (0.16 ± 0.01 g, n = 2). In contrast, spleens from tumor-bearing mice receiving tofacitinib showed only 10% increase in weight (0.18 ± 0.01 g, n = 4) over naive mice, suggesting a drug-mediated reduction in splenic inflammation, consistent with published reports (60). Further, when splenocytes from naive and tumor-bearing mice were analyzed by flow cytometry, tofacitinib treatment resulted in a 10% reduction in overall CD11b+ populations and a 20% reduction in CD68+ populations (Supplemental Figure 8, B and C). Thus, it is likely that short-duration tofacitinib treatments reduce potential non-target sinks for antibody-based agents not only at the tumor site, but at other locations where inflammatory cells are prone to accumulate. Together, these data suggest that tumors with high levels of phagocytic inflammatory cells may divert a significant proportion of anti-cancer antibodies and that reducing their presence in and around a tumor could significantly improve the amount of therapeutic antibody available for interacting with target malignant cells.

Discussion
Previously, we reported that the generation of anti-immunotoxin antibodies in immunocompetent mice was inhibited by tofacitinib, reducing titers by more than 200-fold (41). Here, we extend those findings and report on a second substantial benefit of using tofacitinib, namely the increased delivery of antibody therapeutics to malignant cells, achieved by reducing cytokine signaling and the recruitment of tumor-associated inflammatory cells. Consistent with enhanced delivery, we noted increased immunotoxin efficacy in TNBC and PDAC xenograft tumor models. Expanding on these initial experiments, we demonstrated that tofacitinib also enhanced the activity of an ADC targeting mesothelin in a pancreatic tumor xenograft. In experiments designed to quantify delivery to malignant cells, tofacitinib pretreatment resulted in greater uptake of antibody-based agents into malignant cells and an increased immunotoxin half-life in tofacitinib-treated mice. While tofacitinib-mediated reductions of inflammatory cells in general was not a surprise considering its reported antiinflammatory activity in the joints of rodent models (43) and human RA patients (45), decreased inflammation within tumors and decreased non-target uptake of immunotoxin by inflammatory cells was not anticipated. Our data suggest that depletion of these cell types may explain the in vivo enhancement of antibody-based therapeutics in several xenograft models.

The chronic inflammatory state associated with many cancers often results in the accumulation of innate immune cells associated with wound healing and repair, which respond to cytokines released by the tumor and in turn, release growth factors, angiogenic factors, and cytokines that promote tumor growth, metastases, and immune suppression (61). This polarization of the TME towards an alternative state is predicated on cytokine crosstalk between tumor cells, stroma, and the host immune system, suggesting that targeting common signaling pathways could disrupt a protumorigenic environment (24, 62, 63). Intriguingly, a recent article reported on systemic inflammation with monocyte and neutrophil mobilization that could be abolished by a few treatments with antiinflammatory agents (64). In our study, histological examination of tumor inflammatory cell populations confirmed that TAM and TAN populations were depleted in tofacitinib-treated tumors. Published reports indicate that the proliferation of TAMs within the TME is diminished compared with counterparts in normal tissue; similarly, neutrophils are short-lived cells and rapidly undergo apoptotic cell death, so both inflammatory populations must be continuously recruited to tumors via chemotactic pathways (2). Accumulation of TAMs is an independent predictor of poor patient outcomes in many cancer types, including breast and pancreatic cancers, and are associated with increased resistance to therapeutics (65, 66). Additional depletion of neutrophils in a cancer setting may play a beneficial role, as TANs are associated with disease progression and poor outcomes in many cancers (67–69). Similarly, the modulation of tumor-supporting immune cell populations has been recently identified as a significant component in the effectiveness of cancer treatments with antibodies against immune checkpoint proteins PD-1/PD-L1 (70), and CTLA-4 (71).
Reductions in inflammatory cells after tofacitinib treatment in the 4T-1 syngeneic breast cancer model confirmed that our findings were not peculiar to human xenografts or athymic nude mice. In fact, short-term treatments with tofacitinib achieved qualitative effects similar to other agents designed to inhibit macrophage or monocyte recruitment to tumors, such as novelizumab, carlumab, or RG7155 (2). In PDAC and other tumor models, various anti-macrophage treatments have increased the susceptibility of malignant cells to either chemotherapy or checkpoint inhibitors (72–74), and the use of antiinflammatory drugs in combination with the standard of care in breast (75) and pancreatic (76) cancers has shown some promise. In addition to these combinations, we propose a novel use for agents that inhibit the recruitment of inflammatory cells, namely the increased bioavailability and enhanced uptake of antibodies into malignant cells. In support of this, we report substantial non-target uptake of immunotoxins by inflammatory cells in tumor-bearing mice. Because of the short half-lives of recombinant immunotoxins, uptake was measured 3 hours after injection. Results indicated that at this time point, a majority of tumor-associated immunotoxin was recovered within inflammatory cells in vehicle-treated mice. In tofacitinib-treated mice, there were fewer inflammatory cells containing immunotoxin, and thus we speculate that decreased non-target uptake leads to increased on-target delivery to malignant cells. While these experiments provided a quantitative insight into the short-term fate of immunotoxins, long-term effects were also evident, seen in the enhanced antitumor activity observed with 3 unique antibody-based therapeutic agents.

Clinical evidence suggests that depletion of tumor-associated suppressive cell populations may play a role in enhancing multiple classes of anticancer therapies (77). Gemcitabine specifically induces apoptosis in MDSC populations and depletes neutrophils in human patients (78, 79), while having no effect on T cells, B cells, NK cells, or dendritic cells. Combination of gemcitabine with immunotherapies has proven significantly more effective than immunotherapy or gemcitabine alone, suggesting that depletion of MDSC or neutrophil populations may be a general mechanism to improve patient outcomes (80). Relevant to our study, treatment with gemcitabine in conjunction with immunotoxin resulted in better tumor clearance in vivo than either agent alone, while having no enhancement effect in vitro (81). These studies suggest that compounds that inhibit the expansion or recruitment of immunosuppressive and tumor-promoting immune populations may prove effective at enhancing antibody-based therapies. However, it remains difficult to identify these agents using in vitro screening because contributions of the TME are difficult to duplicate outside the intact animal.

Previous efforts for improving drug delivery were primarily predicated upon 2 different approaches: normalization of the vasculature through antiangiogenesis agents, or depletion of ECM and tumor stromal cells (82). However, recent focus has shifted to reducing the inflammatory state of the tumor itself to stimulate vascular normalization, reduce edema, and deplete protumorigenic inflammatory cells (7). While our study provides evidence that reducing tumor inflammation may enhance the efficacy of tumor-directed antibodies, it has not revealed whether increased antibody delivery reflects only relief from nonspecific uptake by inflammatory cells or if other mechanisms are operative. We have yet to examine whether tofacitinib affects normalization of endothelial vessel organization (83), decreases tumor interstitial pressure due to reduction in inflammation, or reduces matrix proteins that can inhibit therapeutic antibody penetration (84). However, as tofacitinib is approved for treatment of fibrosis and significantly decreases deposition of ECM proteins, especially collagens (85), this may be an additional benefit of using this specific compound. By microscopy, some tofacitinib-mediated reduction in fibrosis within our tumor models was noted, but this was not quantified. Further, when monitoring antitumor effects, possible contributions from reduced levels of cytokines promoting tumor survival or proliferation cannot be excluded. Future studies will focus on these important issues.

Of additional interest, CD11b+ populations are inversely correlated with the effectiveness of checkpoint inhibitor treatments (86, 87). A potential role for tofacitinib in this setting is especially intriguing, as not only does tofacitinib deplete tumor-associated CD11b+ populations, it also suppresses transcription of PD-L1 through a STAT-dependent mechanism (88). As shown in Table 1, we observed a decrease in transcript levels of PD-L1 in the tumors of tofacitinib-treated mice. In conjunction with the observed improvement in tumor access for antibody-based therapeutics, we speculate that these effects could result in tofacitinib enhancement of checkpoint-based immunotherapy agents in poorly responsive cancers, including pancreatic cancers. However, it is unclear how tofacitinib might affect T cell populations required for effective tumor clearance upon checkpoint blockade.

In summary, our data show that tofacitinib, an FDA-approved small-molecule JAK/STAT inhibitor with an acceptable safety profile in humans, alters the TME through suppression of the chemokines that attract inflammatory cells. Broadly, our data suggest that depletion of tumor-associated inflammatory cells
through inhibition of chemokine signaling may improve the treatment efficacy of antibody-based anticancer therapeutics and suggest that tofacitinib or similar antiinflammatory drugs could be used in combination with antibody-based therapeutics.

**Methods**

**Cell culture.** The KLM-1 (PDAC) cell line was derived by Kimura et al. from a liver metastatic lesion (89). The MDA-MB-468 (TNBC) cell line was obtained from the American Type Culture Collection (HTB-132). MDA-MB-468 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS, Glutamax, nonessential amino acids (NEAAs), and sodium pyruvate. KLM-1 cells were cultured in ATCC-formulated RPMI 1640 medium (Thermo Fisher Scientific) with Glutamax, NEAAs, and 10% heat-inactivated FBS.

**Cellular viability.** Cells were plated in 96-well format at 10,000 cells/well. After 24 hours, viability was determined with the CellTiter-Glo Viability Assay Kit (Promega). Data are presented as a percentage of control cells. Data are from at least 2 independent replicate experiments in triplicate.

**Cancer xenograft models.** MDA-MB-468 or KLM-1 tumors were established in 6- to 9-week-old female nude athymic mice (Charles River Laboratories). After tumor volume had reached approximately 100 mm³, mice were randomized into treatment groups (n = 6–8 mice per group) and treated with vehicle alone, tofacitinib (5 mg/kg, twice), HB21-PE40 (0.1 mg/kg), or LMB-100 (2.5 mg/kg), or the combination of tofacitinib and immunotoxin. Mice were treated every other day for 1 (MDA-MB-468) or 2 (KLM-1) treatment cycles with 4 injections per cycle. Tofacitinib was dissolved in 30% PEG300 and 5% Tween 80 in PBS and injected i.p. once in the morning with the second injection 8 hours later to mimic the twice-daily human dosing schedules. Immunotoxin injections were performed every other day via tail vein for each mouse in conjunction with the second daily tofacitinib dosing. Anetumab ravtansine (provided by Bayer AG) was diluted in the supplied vehicle (10 mM histidine, 130 mM glycine, 5% sucrose in water). Each treatment cycle consisted of 10 mg/kg tofacitinib (3 times) and 10 mg/kg anetumab ravtansine (once), with mice treated once per day with tofacitinib and anetumab ravtansine delivered via tail vein concurrent with the third dose. Tumor volume and animal weight were measured at least 3 times weekly. Tumor volume was calculated as 0.5 × (l × w²). Animals were euthanized by CO₂ inhalation once tumors reached 1,200 mm³, became necrotic, or animals became moribund. Time to endpoint for each mouse was displayed on a Kaplan-Meyer plot and statistical significance calculated by log-rank test.

**Syngeneic tumor model.** 4T-1 tumors were established in 6- to 9-week-old female BALB/c mice (Charles River Laboratories). After tumor volume had reached approximately 200 mm³, mice were randomized into treatment groups (n = 6–8 mice per group) and were left untreated, treated with vehicle alone, or tofacitinib (5 mg/kg, twice). Mice received 4 treatments every other day and were euthanized once tumors reached 1,200 mm³.

**Nanostring analysis.** Total RNA was purified from homogenized KLM-1 tumors 24 hours after treatment with 2 cycles of vehicle or tofacitinib (1 cycle: 5 mg/kg tofacitinib twice at 8-hour intervals, then a 24-hour rest period) using the QIAGEN RNeasy RNA Purification kit. RNA from untreated, vehicle-treated, or tofacitinib-treated tumors (n = 3 tumors per treatment group) was loaded onto the Nanostring nCounter PanCancer Immune Profiling Panel (Nanostring Technologies Inc) according to manufacturer’s specifications. mRNA transcript counts were analyzed using NSolver software (Nanostring Technologies), with differential expression compared by pooled cluster analysis. Transcript differences between vehicle and tofacitinib-treated RNA pools were ordered according to the magnitude of fold change and transcripts with greater than 2-fold changes are displayed in Tables 1 and 2.

**ELISA.** Cytokine levels were determined by testing serum from tofacitinib-treated, vehicle-treated, or untreated tumor-bearing mice using the Mouse IL-6 Quantikine ELISA (M6000B), Mouse CCL2/JE/MCP-1 Quantikine ELISA (MJE00), Mouse CXCL2/MIP-2 Quantikine ELISA Kit (MMB00), Mouse CCL4/MIP-1 beta Quantikine ELISA Kit (MMB00), or Mouse CCL3/MIP-1 alpha Quantikine ELISA (MMA00) (all R&D Systems). Results were compared to cytokine levels detectable in serum from naive mice and significance was assessed using unpaired 2-tailed t tests.

**Tumor uptake and flow cytometry.** Mice were pretreated with 2 cycles of vehicle or tofacitinib (1 cycle: 5 mg/kg twice at 8-hour intervals, then a 24-hour rest period) and then injected via tail vein with 50 μg of Alexa Fluor-labeled immunotoxin or 10 μg fluorescently labeled antibody. After 3 hours, tumors were harvested, minced, and resuspended in HBSS supplemented with Liberase TL (0.2 U/ml) (Roche Life Sciences).
minutes. Urea concentration was determined by measuring OD540. Two-fold dilutions of urea (0.75–30 μg urea in 60 minutes).

Arginase–1 quantification. The protocol for arginase–1 quantification was adapted from Corraliza et al. (56). Equal volumes of tumor supernatant and assay buffer (10 mM MnCl₂, 50 mM Tris-HCl, pH 7.5) were mixed and placed at 55°C for 10 minutes to activate the enzyme. Arginase hydrolysis was initiated by the addition of 0.5 M arginine to the lysate and incubation at 37°C for 60 minutes. The reaction was quenched with the addition of a 1:3:7 mixture of sulfuric acid, phosphoric acid, and water. α-isornitrosopropiophene (ISPf, 9%) dissolved in ethanol was added to the quenched reaction and incubated at 100°C for 45 minutes. Urea concentration was determined by measuring OD540. Two-fold dilutions of urea (0.75–30 μg) were used to generate a standard curve. One unit of enzyme activity was defined as the amount of arginase that catalyzes the formation of 1 μg urea in 60 minutes.

Statistics. All experimental error bars display standard deviation, with all P values calculated for 95% confidence intervals. Statistics were analyzed using GraphPad Prism. Unpaired 2-tailed t tests were performed for concentrations of tofacitinib tested in viability assays, comparing vehicle treatment to immunotoxin plus tofacitinib. Xenograft tumor volumes were compared at experimental endpoints by unpaired 2-tailed t test between treatment groups, with P values reported for comparisons between treatment group and vehicle-treated mice (asterisks) or between immunotoxin- and combination-treated groups (†). Changes in survival were assessed using a log-rank test. Serum ELISA or tumor arginase–1 values from vehicle-
and tofacitinib-treated mice were compared by unpaired 2-tailed t test. Differences in tumor uptake of fluorescently labeled proteins were compared by unpaired 2-tailed t tests, comparing values for vehicle-treated and tofacitinib-treated mice. Differences in tumor immune cell counts in tofacitinib and vehicle-treated IHC samples were compared by unpaired 2-tailed t test.

Study approval. All animal experiments were performed in accordance with NIH guidelines and approved by the National Cancer Institute Animal Care and Use Committee.

Author contributions
NS planned and conducted experiments, and wrote and edited the manuscript. AA and CA planned experiments and edited the manuscript. SMH and MG conducted experiments and edited the manuscript. DF planned experiments, and wrote and edited the manuscript.

Acknowledgments
This research was supported by the intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute and by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Address correspondence to: David FitzGerald, Center for Cancer Research, National Cancer Institute, Building 37, Room 5124, Bethesda, Maryland 20892-4255, USA. Phone: 240.760.7838; email: fitzgerdl@mail.nih.gov.


57. Weldon JE, et al. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity,


54. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

53. DeNardo DG, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties

52. Fridlender ZG, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN.


50. Jewett A, Bonavida B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor

49. Mason-Osann E, Hollevoet K, Niederfellner G, Pastan I. Quantification of recombinant immunotoxin delivery to solid tumors

47. Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseas-


45. Hodge JA, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthri-


35. Kreitman RJ, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in


33. Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of target-

32. Sadanandam A, Colisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-


29. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer.


17. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-


15. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-


10. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-


8. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-

7. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-


5. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-


2. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-

1. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-

0. Sadanandam A, Collisson E, Gibb W, Hanahan D, Gray J. Identification of molecular subtypes in pancreatic adenocarcino-

insight.jci.org


